- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Biogen Inc (1BIIB)Biogen Inc stock price live, this page displays NASDAQ BIIB stock exchange data. View the BIIB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Biogen Inc real time stock price chart below.
What Is the Biogen Inc Stock Price Today?
The Biogen Inc stock price today is 154.80.
What Is the Stock Symbol for Biogen Inc?
The stock symbol for Biogen Inc is "BIIB."
What Stock Exchange Does Biogen Inc Trade On?
Biogen Inc is listed and trades on the NASDAQ stock exchange.
Is Biogen Inc a Good Stock to Buy?
Determining whether Biogen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BIIB quote. (ISIN: US09062X1037)
What Is the Biogen Inc Stock Price Today?
The Biogen Inc stock price today is 154.80.
What Is the Stock Symbol for Biogen Inc?
The stock symbol for Biogen Inc is "BIIB."
What Stock Exchange Does Biogen Inc Trade On?
Biogen Inc is listed and trades on the NASDAQ stock exchange.
Is Biogen Inc a Good Stock to Buy?
Determining whether Biogen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the BIIB quote. (ISIN: US09062X1037)
154.80
0.00(0.00%)
Real-time Data
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
154.00
155.25
52 wk Range
146.70
244.60
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
154.00155.25
52 wk Range
146.70244.60
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
UnlockN/A
(N/A)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
Unlock1BIIB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Technical Analysis
Neutral
Price Target
254.26
Upside
+58.07%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Currently not supported.
- Biogen Idec Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Biogen Idec Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Biogen Idec Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Biogen Inc Company Profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Compare 1BIIB to Peers and Sector
Metrics to compare | 1BIIB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1BIIBPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 24.5x | −0.7x | |
PEG Ratio | 0.00 | 0.20 | 0.00 | |
Price/Book | 0.0x | 2.6x | 2.6x | |
Price / LTM Sales | 0.0x | 6.0x | 3.2x | |
Upside (Analyst Target) | 0.0% | 59.8% | 46.4% | |
Fair Value Upside | Unlock | 3.0% | 6.9% | Unlock |
People Also Watch
FAQ
What Is the Biogen (1BIIB) Stock Price Today?
The Biogen stock price today is 154.80
What Stock Exchange Does Biogen Trade On?
Biogen is listed and trades on the Milan stock exchange.
What Is the Stock Symbol for Biogen?
The stock symbol for Biogen is "1BIIB."
What Is the Biogen Market Cap?
As of today, Biogen market cap is 22.32B.
From a Technical Analysis Perspective, Is 1BIIB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.